The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Congresses
Poster
Dato-DXd
ESMO Asia 2025 | December 5-7, 2025
Lung Cancer
A multicenter, real-world study of treatment patterns and clinical outcomes of later-line therapy in Chinese patients with advanced non-small cell lung cancer harboring non-actionable genomic alterations (RECAP Study)
Hanxiao Chen
View presentation
Mini-Oral
T-DXd
ESMO Asia 2025 | December 5-7, 2025
Breast Cancer
DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs ddAC-THP for high-risk HER2+ early breast cancer
Nadia Harbeck
View presentation
Poster
T-DXd
ESMO Asia 2025 | December 5-7, 2025
Gastric Cancer
First-line trastuzumab deruxtecan 5.4 mg/kg and fluoropyrimidine with pembrolizumab in advanced HER2+ gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: Updated results from DESTINY-Gastric 03 part 2F
Yelena Y. Janjigian
View presentation
Poster
HER3-DXd
ESMO Asia 2025 | December 5-7, 2025
Breast Cancer
HERTHENA-Breast01: A phase 1b/2, multicenter, open-label, dose-finding study to evaluate the safety and antitumor activity of patritumab deruxtecan (HER3-DXd) in human epidermal growth factor receptor 2–positive unresectable locally advanced or metastatic breast cancer
Hiroji Iwata
View presentation
Poster
I-DXd
ESMO Asia 2025 | December 5-7, 2025
Esophageal Cancer
IDeate-Esophageal01: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) in patients with pretreated advanced/metastatic esophageal squamous cell carcinoma
Ken Kato
View presentation
Oral
I-DXd
ESMO Asia 2025 | December 5-7, 2025
Lung Cancer
Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: Asian subgroup analysis from the phase 2 IDeate-Lung01 study
Hidetoshi Hayashi
View presentation
Poster
T-DXd
ESMO Asia 2025 | December 5-7, 2025
Lung Cancer
Patient characteristics, HER2 testing, and treatment patterns in advanced italicize HER2 (italicize ERBB2)-mutant NSCLC in real-world clinical practice
Timothy Clay
View presentation
Poster
T-DXd
ESMO Asia 2025 | December 5-7, 2025
Breast Cancer
Preliminary analysis for baseline characteristics and treatment patterns of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low breast cancer: First interim analysis of REFRESH study
Yongmei Yin
View presentation
Oral
R-DXd
ESMO Asia 2025 | December 5-7, 2025
Gynecologic Cancers
Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: A subgroup analysis of Asian patients from the phase 2, dose-optimization part of REJOICE-Ovarian01
Jung-Yun Lee
View presentation
Mini-Oral
T-DXd
ESMO Asia 2025 | December 5-7, 2025
Breast Cancer
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line treatment of Asian patients with HER2+ advanced/metastatic breast cancer: A DESTINY-Breast09 analysis
Toshimi Takano
View presentation
Pages: 1  2  
Connect with an MSL
Linkedin Icon Twitter Icon

©2024 Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24